Efficacy and safety of tyrosine kinase inhibitors plus PD-1 inhibitor in patients with transarterial chemoembolization- refractory hepatocellular carcinoma: a two-center retrospective study

• Published in: Frontiers in oncology Vol. 13; p. 1231359
• Main Authors: Gao, Ya, Lu, Haohao, Xiong, Zhifan
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 2023
• Subjects: camrelizumab; hepatocellular carcinoma; overall survival; PD-1; TACE-refractory; tyrosine kinase inhibitor; overall survival; TACE-refractory; tyrosine kinase inhibitor; PD-1; hepatocellular carcinoma; camrelizumab

To investigate the efficacy and safety of tyrosine kinase inhibitors (TKIs: sorafenib and lenvatinib) plus PD-1 inhibitor (camrelizumab) versus TKIs alone in transarterial chemoembolization-refractory (TACE-refractory) hepatocellular carcinoma (HCC). Data of TACE-refractory HCC patients treated with...